QGP-1人胰腺癌细胞

价 格:¥3000

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1365

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameQGP-1
SynonymsQGP 1; QGP1
AccessionBTCC-1365
Resource Identification InitiativeTo cite this cell line use: QGP-1 (BTCC-1365)
CommentsPart of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: NCI RAS program mutant KRAS cell line panel.
Population: Japanese.
Doubling time: ~3.5 days (PubMed=7227711); 61 hours (PubMed=25984343); 1.6 +- 0.3 days (PubMed=29330294); 40-50 hours (Note=Lot 04152003), ~2 days (Note=Lot 02162009), ~42 hours (Note=Lot 04112012), ~74 hours (Note=Lot 05312016) (JCRB=JCRB0183).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: QGP; CGH-DB=9375-4; GEO=GSM600373.
Misspelling: QCP-1; DOI=10.5772/30884.
Derived from site: In situ; Pancreas, islets of Langerhans; UBERON=UBERON_0000006.
Cell type: Pancreatic delta cell; CL=CL_0000173.
Sequence variations
  • Mutation; HGNC; 583; APC; Simple; p.Arg2166Gln (c.6497G>A); ClinVar=VCV000230267; Zygosity=Heterozygous (PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=21607521; PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leufs*25 (c.293delC); Zygosity=Heterozygous (PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap).
HLA typingSource: PubMed=26589293
Class I
HLA-AA*24:02,24:02
HLA-BB*15:11,67:02
HLA-CC*01:21,12:03
Class II
HLA-DRDRB1*13:26,15:02
Genome ancestrySource: PubMed=30894373

Origin% genome


African0
Native American0
East Asian, North82.5
East Asian, South17.02
South Asian0.48
European, North0
European, South0
DiseasePancreatic somatostatinoma (NCIt: C95595)
Somatostatinoma (ORDO: Orphanet_97283)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cellMale
Age at sampling61Y
CategoryCancer cell line
STR profileSource(s): Cosmic-CLP; JCRB; PubMed=25877200; PubMed=29444910

Markers:
AmelogeninX
CSF1PO10,12
D3S135814,17
D5S81812
D7S82012
D8S117914
D13S31713
D16S53910,12 (Cosmic-CLP; JCRB; PubMed=29444910)
12 (PubMed=25877200)
D18S5113
D21S1129
FGA21,23
Penta D13
Penta E5,24
TH016,9
TPOX8,11
vWA14,17,18 (JCRB)
14,18 (Cosmic-CLP; PubMed=25877200; PubMed=29444910)

Run an STR similarity search on this cell line
Web pageshttps://www.cellosaurus.org/pawefish/PancCellLineDescriptions/QGP-1.html
Publications

PubMed=7227711; DOI=10.20772/cancersci1959.71.5_596
Kaku M., Nishiyama T., Yagawa K., Abe M.
Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma.
Gann 71:596-601(1980)

PubMed=6205259; DOI=10.1016/0161-5890(84)90028-2
Kuroki M., Kuroki M., Ichiki S., Matsuoka Y.
Identification and partial characterization of the unglycosylated peptide of carcinoembryonic antigen synthesized by human tumor cell lines in the presence of tunicamycin.
Mol. Immunol. 21:743-746(1984)

PubMed=1971195
Iguchi H., Hayashi I., Kono A.
A somatostatin-secreting cell line established from a human pancreatic islet cell carcinoma (somatostatinoma): release experiment and immunohistochemical study.
Cancer Res. 50:3691-3693(1990)

PubMed=8426738
Kalthoff H., Schmiegel W., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E., Maurer J., Maacke H., Deppert W.
p53 and K-RAS alterations in pancreatic epithelial cell lesions.
Oncogene 8:289-298(1993)

PubMed=21607521; DOI=10.3892/or.1.6.1223
Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.
Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.
Oncol. Rep. 1:1223-1227(1994)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::aid-ijc1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

DOI=10.5772/30884
Ruckert F., Pilarsky C., Grutzmann R.
Establishment of primary cell lines in pancreatic cancer.
(In) Pancreatic cancer. Molecular mechanism and targets; Srivastava S. (eds.); pp.259-274; InTechOpen; London (2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22929519; DOI=10.3791/4218
Wong C., Vosburgh E., Levine A.J., Cong L., Xu E.Y.
Human neuroendocrine tumor cell lines as a three-dimensional model for the study of human neuroendocrine tumor therapy.
J. Vis. Exp. 66:e4218.1-e4218.7(2012)

PubMed=23119007; DOI=10.1371/journal.pone.0048411
Li S.-C., Martijn C., Cui T., Essaghir A., Luque R.M., Demoulin J.-B., Castano J.P., Oberg K., Giandomenico V.
The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
PLoS ONE 7:E48411-E48411(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25612765; DOI=10.1530/JME-14-0304
Vandamme T., Peeters M., Dogan F., Pauwels P., Van Assche E., Beyens M., Mortier G., Vandeweyer G., de Herder W., Van Camp G., Hofland L.J., Op de Beeck K.
Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1.
J. Mol. Endocrinol. 54:137-147(2015)

PubMed=26087898; DOI=10.1016/j.cancergen.2015.04.002
Boora G.K., Kanwar R., Kulkarni A.A., Pleticha J., Ames M., Schroth G., Beutler A.S., Banck M.S.
Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Cancer Genet. 208:374-381(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29330294; DOI=10.1158/1541-7786.MCR-17-0163
Benten D., Behrang Y., Unrau L., Weissmann V., Wolters-Eisfeld G., Burdak-Rothkamm S., Stahl F.R., Anlauf M., Grabowski P., Mobs M., Dieckhoff J., Sipos B., Fahl M., Eggers C., Perez D., Bockhorn M., Izbicki J.R., Lohse A.W., Schrader J.
Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model.
Mol. Cancer Res. 16:496-507(2018)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051
Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep. 22:1889-1902(2018)

PubMed=29444910; DOI=10.1530/ERC-17-0445
Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R., Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Endocr. Relat. Cancer 25:367-380(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

CLPUB00598
Behrang Y.
Establishment and characterization of a new human, highly differentiated and functionally active tumor model of a pancreatic neuroendocrine tumor.
Thesis MD (2020), University of Hamburg, Germany

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

PubMed=36180704; DOI=10.1007/978-1-0716-2593-4_35
Zibolka J., Bahr I., Peschke E., Muhlbauer E., Bazwinsky-Wutschke I.
Human and rodent cell lines as models of functional melatonin-responsive pancreatic islet cells.
Methods Mol. Biol. 2550:329-352(2022)

Cross-references
Cell line databases/resourcesCell_Model_Passport; SIDM00360
CGH-DB; 9375-4
Cosmic-CLP; 1298534
DepMap; ACH-000347
LINCS_LDP; LCL-1754
Anatomy/cell type resourcesBTO; BTO:0005500
Biological sample resourcesBioSample; SAMN03472832
BioSample; SAMN03472892
BioSample; SAMN10988306
Cell line collections (Providers)JCRB; JCRB0183
Chemistry resourcesGDSC; 1298534
PharmacoDB; QGP1_1280_2019
Encyclopedic resourcesWikidata; Q54948822
Experimental variables resourcesEFO; EFO_0006741

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部